Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4281 trials

DBS for Depression

NCT06096207
Recruiting
Conditions Treatment Resistant Depression
Phase PHASE1
Enrollment 20
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this clinical trial is to demonstrate the feasibility and safety of deep brain stimulation in treatment resistant depression. The main questions it aims to answer are: * Is deep brain stimulation effective in treating treatment resistant depression? * Does deep brain stimulation improve overall clinical well-being and functioning? Participants will be implanted with a deep brain stimulation device. They will then be monitored over a 5-year period by using multiple questionnaires to track their depression symptoms. The device will be turned off at certain time points, unbeknown to the participant, to show the efficacy of the device when it is turned on. The device will be ON for 8.5 months and OFF for 3.5 months during the first year. Researchers will compare questionnaire scores when the device is off versus on to see if the device is working in reducing depression.

Design

Study type: Interventional Phases: Phase1 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Double

Interventions / Regimen

  • Device: Medtronic SenSight Directional DBS lead — At the ninth month post DBS implantation, the participant will enter a discontinuation phase of a duration of 6 weeks. The device will be turned on and off without participants' knowledge. After 6 weeks, the device will be turned back on if it was off. Whether the stimulation is active or not, it will be double blinded.

Primary Outcomes

  • Montgomery-Asberg Depression Rating Scale (MADRS) (12 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1
Status: Recruiting
Start Date: 2023-10-18
Completion: 2038-10-18
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 20 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Northwell Health
Collaborators: Medtronic
Principal Investigators:
  • Albert J Fenoy, MD (PRINCIPAL_INVESTIGATOR) - Northwell Health
Contact Information
Study Contact:
Jeanna Boltz
7184708021
Jboltz@northwell.edu
Samantha Gonzalez
718-470-4152
sgonzalez30@northwell.edu
Zucker Hillside Hospital
Albert J Fenoy, MD
Zucker Hillside Hospital
Interventions
  • Device: Medtronic SenSight Directional DBS lead — At the ninth month post DBS implantation, the participant will enter a discontinuation phase of a duration of 6 weeks. The device will be turned on and off without participants' knowledge. After 6 weeks, the device will be turned back on if it was off. Whether the stimulation is active or not, it will be double blinded.
Study Locations (1 sites)
Zucker Hillside Hospital, Queens, New York 11004 United States
Eligibility Criteria
Inclusion Criteria: 1. Major Depression Disorder (MDD) or Bipolar Disorder (I /II) diagnosed by Structured Clinical Interview for DSM-V (SCID I/DSM-V) 2. Age 18 - 65 years. 3. 24-item Hamilton Depression Rating Scale (HDRS) score of at least 21 on the first 17 items and/or Montgomery-Asburg Depression Rating Scale (MADRS) score of at least 21. 4. World Health Organization Disability Assessment Scale 2.0(WHODAS2.0) score of 19 or more 5. A recurrent (equal or \>4 episodes) or chronic (episode duration equal or higher \>2 years) course AND a minimum of 5 years since the onset of the first depressive episode. Major impairment in functioning or potentially severe medical outcomes (repeated hospitalizations, serious suicidal or other self-injurious behavior) over lifetime history as determined by an investigator 6. As determined by the study psychiatrist/investigator, has treatment resistant depression defined as failure to respond to: 6.1. Adequate trials (equal or \>6 weeks at an adequate dose) of primary antidepressants from at least 3 different classes AND; 6.2. adequate trials (equal\>4 weeks at an adequate dose) of augmentation/combination of a primary antidepressant using at least 2 different augmenting/combination agents (lithium, T3, stimulants,neuroleptics, anticonvulsants, buspirone, or a second primary antidepressant) AND; 6.3 An adequate trial of ECT (\>6 bilateral treatments), or inability to tolerate an adequate ECT trial, AND; 6.4 An adequate trial of individual psychotherapy (\>20 sessions with an experienced psychotherapist). 7. Able to comply with the operational and administrative requirements of participation in the study. 8. Able to give written informed consent 9. Major Depressive Disorder (MDD) or Bipolar Disorder (I/II) is the primary psychiatric diagnosis in the medical opinion of an investigator. 10. On a stable psychiatric medication regimen beginning at least 6 weeks prior to enrollment and continuing through the first 6 months of the study, as determined by the investigator. Psychiatric medication changes can be made during the entirety of the subject's study participation but would be limited to the clinical judgment of the PI/study psychiatrist. 11. At enrollment, provides the following information from at least two (2) verifiable contacts who reside within a 10-mile radius of the patient: name, relationship to patient, address (email mail); and telephone (mobile, home, work as applicable). 12. Agrees to allow medical records requests and communications of any type to any and all health care providers who have seen the patient within five years of screening or enrollment. 13. For the duration of study participation, agrees to be followed by a licensed psychiatrist and/or other licensed mental health practitioner on a regularly scheduled basis. 14. FOR AGES 18-21: An average of at least 3 in the following subdomains on the Psychological Maturity Scale (PMS): questions 1-6, "Ego Resilience"; questions 7-13, "Self-Awareness"; questions 14-17, "Autonomy"; questions 18-21, Flexibility". 15. FOR AGES 18-21: Residing with a caretaker or having oversight of a caretaker. Exclusion Criteria 1. Patients with any lifetime history of psychosis or psychotic disorder, according to DSM-V diagnostic criteria, or in the medical opinion of the PI/study psychiatrist. 2. Any finding on the preoperative magnetic resonance imaging (MRI) scan that, in the opinion of the principal investigator and after consultation with the neuroradiologist, is, or might be, considered clinically significant such that participation in the study: (a) seems likely to increase the medical risk to the subject sufficient to outweigh the potential benefit to study participation; (b) seems likely to jeopardize the subject's ability to complete the study or fulfill all study requirements per protocol; or (c) may impact he integrity of the data or the validity of the results. 3. Any previous surgery to destroy the treatment target (superolateral MFB) rendering it either unilaterally or bilaterally damaged such that it cannot be effectively stimulated, as visualized by pre-operative MRI scans, in the medical opinion of the PI 4. Any surgical contraindications to undergoing DBS, including labeled contraindications for DBS and/orinability to undergo presurgical MRI (cardiac pacemaker, implantable defibrillator or other implantablestimulator, pregnancy, metal in body, severe claustrophobia), infection, coagulopathy, inability to undergo an awake operation, significant cardiac or other medical risk factors for surgery. DBS contraindications include patients who are unable to properly operate the neurostimulator, and patientswho will be exposed to MRI or diathermy. MRI and diathermy (e.g., shortwave diathermy, microwave diathermy or therapeutic ultrasound diathermy) are contraindicated because the energy can be transferred through the implanted System (or any of the separate implanted components), which can cause tissue damage and can result in severe injury or death. Diathermy can damage parts of the neurostimulation system. 5. Refusal of an adequate trial of ECT in the medical opinion of the study psychiatrist or PI following consultation with a study psychiatrist. 6. History of stimulation intolerance in any area of the body. 7. Within six (6) months of the enrollment date, has been diagnosed with, or has met the diagnostic criteria for, a substance abuse disorder (SUD) according to DSM-V criteria. 8. Women of childbearing potential who, at enrollment or during the study: (a)have a positive urine pregnancy test; (b) are heterosexually active without the usage of a medically acceptable, highly effect contraceptive method\* (≤1% pregnancy rate); or (c) are planning to become pregnant during the 60-month course of this study, as determined by the PI. \*Examples include tubal ligation, vasectomized partner, IUD or IUS (intrauterine device or system), and long-acting reversible contraceptives (LARC). 9. Active suicidal ideation with intent, suicide attempt within the last six months, more than three suicide attempts within the last two years, or serious suicide risk as determined by the study psychiatrists. 10. Participation in another drug, device, or biologics trial within the preceding 30 days 11. Presence of a condition requiring routine MRIs. 12. Presence of a condition requiring diathermy. 13. Subject is on anticoagulant medication. 14. Prior to enrollment or during the course of the study and in the opinion of the PI, has a history of an medical, psychiatric, physical or non-physical disease, disorder, condition, injury, or disability; or has a non-medical reason (e.g., financial, logistical, personal, other) that: (a) may pose a significant risk to the patient; (b) may increase the possibility that the subject is unlikely to successfully complete all of the requirements of the study according to the study protocol; or (c) may adversely impact the integrity of the data or the validity of the study results. 15. Subjects without a fixed home address or stable living situation, in the opinion of the Principal Investigator. 16. Subjects involved in activities involving significant radiation exposure in the past year. 17. Receiving TMS after DBS implantation 18. Any mania or manic episodes within 5 years of enrollment according to DSM-V diagnostic criteria, or in the medical opinion of the PI/study psychiatrist
Conditions Pulmonary Arterial Hypertension, Right H...
Phase PHASE2
Enrollment 60
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This is a Phase 2, single-center, randomized placebo controlled trial of valsartan (an angiotensin receptor blocker) in adults with pulmonary arterial hypertension. The study will evaluate the safety and clinical efficacy of a 24-week course of valsartan.

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Quadruple

Interventions / Regimen

  • Drug: Valsartan 40 mg — Valsartan 40mg twice daily for 24 weeks.
  • Drug: Placebo — Placebo twice daily for 24 weeks.

Primary Outcomes

  • Six-minute walk distance (0 to 24 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2024-02-28
Completion: 2027-07-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 60 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Washington
Collaborators: National Heart, Lung, and Blood Institute (NHLBI)
Principal Investigators:
  • Peter Leary, MD, PhD (PRINCIPAL_INVESTIGATOR) - University of Washington
Contact Information
Study Contact:
Laurie Hogl, RRT
206.543.8334
lalnaser@uw.edu
Nancy Liston, MS
206.543.8334
nmliston@uw.edu
Laurie Hogl
2065438334
lalnaser@uw.edu
University of Washington Medical Center
Interventions
  • Drug: Valsartan 40 mg — Valsartan 40mg twice daily for 24 weeks.
  • Drug: Placebo — Placebo twice daily for 24 weeks.
Study Locations (1 sites)
University of Washington Medical Center, Seattle, Washington 98195 United States
Eligibility Criteria
Inclusion Criteria: 1. Male or female, age 18 to 80 2. WHO Group 1 Pulmonary Arterial Hypertension 3. NYHA Functional Class II, III, or IV at screening (Appendix 2 for Functional Class Decision Aid) 4. Right heart catheterization within five years demonstrating a mean pulmonary arterial pressure of ≥25 mmHg, occlusion pressure of ≤15 mmHg, and resistance ≥ 3 wood units 5. Participants with a right heart catheterization within five years demonstrating a mean pulmonary arterial pressure of ≥ 25 mmHg and occlusion pressure of 15 - 20 mmHg will be considered for inclusion if the pulmonary vascular resistance ≥ 9 wood units and they are being treated with pulmonary arterial hypertension specific therapy 6. Able to walk with/without a walking aid for a distance of at least 50 meters Exclusion Criteria: 1. Pregnant or lactating 2. Non-group 1 pulmonary hypertension or veno-occlusive disease 3. History of interstitial lung disease, unless subject has collagen vascular disease and has pulmonary function testing conducted within 12 months demonstrating a total lung capacity or vital capacity of ≥ 60 % 4. Has received or will receive an investigational drug, device, or study within 30 days or during the course of study 5. ACE-inhibitor, ARB or ARNI use within 30 days of randomization. 6. Left sided myocardial disease as evidenced by left ventricular ejection fraction \< 40% 7. Any other clinically significant illness or abnormal laboratory values (measured during the Screening period) that, in the opinion of the Investigator, might put the subject at risk of harm during the study or might adversely affect the interpretation of the study data 8. Anticipated survival less than 1 year due to concomitant disease 9. Allergy or angioedema with ACE-inhibitor use 10. Potassium \>5mEq/L or sCr \>2mg/dL at screening 11. SBP \<90mmHg at screening
Conditions NSCLC, Breast Cancer, HNSCC, Locally Adv...
Phase PHASE2
Enrollment 200
Locations 82 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This study is a multicenter, open-label, phase II study of YL202 in China to evaluate the efficacy, safety, and PK characteristics of YL202 in the following selected patients with advanced solid tumors.

Design

Study type: Interventional Phases: Phase2 Allocation: Non Randomized Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: YL202 should be intravenously infused — For each patient, YL202 should be intravenously infused over 60±10 min.

Primary Outcomes

  • ORR assessed according to RECIST v1.1 (By the end of trial date, approximately within 36 months)
  • Determination of the recommended dose of YL202 in the pivotal clinical study (By the end of trial date, approximately within 36 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2023-12-15
Completion: 2028-11
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 200 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: MediLink Therapeutics (Suzhou) Co., Ltd.
Contact Information
Study Contact:
Coordinator Clinical operation director
+86 0512-62858368
clinicaltrials@medilinkthera.com
Anhui Tumour Hospital
Coordinator Clinical operation director
+86 0512-62858368
clinicaltrials@medilinkthera.com
The first affiliated hospital of Anhui Medical University
Coordinator Clinical operation director
+86 0512-62858368
clinicaltrials@medilinkthera.com
The Second Hospital of Anhui Medical University
Interventions
  • Drug: YL202 should be intravenously infused — For each patient, YL202 should be intravenously infused over 60±10 min.
Study Locations (82 sites)
Anhui Tumour Hospital, Hefei, Anhui China
The first affiliated hospital of Anhui Medical University, Hefei, Anhui China
The Second Hospital of Anhui Medical University, Hefei, Anhui China
Beijing Cancer hospital, Beijing, Beijing Municipality China
Beijing Tsinghua Chang Gung Hospital, Beijing, Beijing Municipality China
Peking University Third Hospital, Beijing, Beijing Municipality China
Chinese First Affiliated Hospital of Army Medical University of the People's Liberation Army, Chongqing, Chongqing Municipality China
Chongqing University Affiliated Tumor Hospital, Chongqing, Chongqing Municipality China
The first affiliated hospital of Chongqing Medical University, Chongqing, Chongqing Municipality China
The Second Affiliated Hospital of Chongqing Medical University, Chongqing, Chongqing Municipality China
Eligibility Criteria
Inclusion Criteria: 1. Subjects who are aware of relevant trial information before the start of the trial, and voluntarily sign and date on the informed consent form (ICF). 2. Subjects aged from 18-75 (inclusive) years. 3. Histologically or cytologically confirmed at diagnosis of NSCLC/BC/HNSCC/other locally advanced or metastatic solid tumors including but not limited to colorectal cancer, HER2-positive gastric cancer, cervical cancer, ovarian cancer, etc.. 4. At least one extracranial measurable lesion according to RECIST 1.1. 5. Archived or fresh tumor tissue samples can be provided. 6. With Eastern Cooperative Oncology Group performance status (ECOG PS) score of 0 or 1. 7. The function of organs and bone marrow meets the requirements within 7 days before the first dose. 8. Female subjects of childbearing potential must agree to adopt highly effective contraceptive measures from screening throughout the study period and within at least 6 months after the last dose of the investigational product. Male subjects must agree to adopt highly effective contraceptive measures from screening throughout the study period and within at least 6 months after the last dose of the investigational product. 9. With expected survival ≥ 3 months. 10. Be capable of and willing to comply with the visits and procedures stipulated in the study protocol. Exclusion Criteria: 1. With prior drug therapy targeting HER3 (including antibodies, antibody-drug conjugates \[ADCs\]), chimeric antigen receptor T-cell immunotherapy (CAR-T), and other drugs). 2. Previously intolerant to topoisomerase I inhibitors or ADC therapy composed of topoisomerase I inhibitors. 3. Are participating in another clinical study, unless it is an observational (non-interventional) clinical study or in the follow-up period of an interventional study. 4. The washout period from the previous anti-tumor therapy is insufficient before the first dose of the investigational product. 5. Patients who have received major surgery (excluding diagnostic surgery) within 4 weeks before the first dose of the investigational product or those who are expected to receive major surgery during the study. 6. Prior treatment with allogeneic bone marrow transplantation or solid organ transplantation. 7. Prior treatment with systemic steroids (prednisone \> 10 mg/day or equivalent) or other immunosuppressive treatment within 2 weeks before the first dose of the investigational product. 8. Patients who have received any live vaccine within 4 weeks before the first dose of the investigational product or those who plan to receive live vaccine during the study period. 9. With meningeal metastasis or cancerous meningitis. 10. With brain metastasis or spinal cord compression. 11. Patients with uncontrolled or clinically significant cardiovascular diseases. 12. Clinically significant complicated pulmonary disorders. 13. Patients diagnosed with Gilbert syndrome. 14. Those with uncontrolled effusion in the third space requiring repeated drainage. 15. With a medical history of gastrointestinal perforation and/or fistula within 6 months before the first dose, or with active gastric and duodenal ulcers, ulcerative colitis, or other gastrointestinal diseases that may lead to hemorrhage or perforation according to the investigator. 16. With serious infection before the first dose. 17. With known human immunodeficiency virus (HIV) infection. 18. With active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection. 19. With a medical history of any other primary malignancies within 5 years before the first dose of the investigational product. 20. Unrelieved toxicity of previous anti-tumor therapy. 21. With a history of severe hypersensitivity to inactive ingredients in the raw materials and drug product or other monoclonal antibodies. 22. Lactating women, or women who are confirmed pregnant via a pregnancy test within 3 days before the first dose. 23. With any diseases, medical conditions, organ system dysfunction, or social conditions that may interfere with the ability of subjects to sign the ICF, adversely affect the ability of subjects to cooperate and participate in the study, or affect the interpretation of study results, including but not limited to mental illness or substance/alcohol abuse, in the opinion of the investigator.
Conditions Diabetes Mellitus, Type 2, PreDiabetes, ...
Phase NA
Enrollment 7500
Locations 125 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

TRANSFORM is a prospective, randomized, open blinded endpoint (PROBE), event-driven, pragmatic trial in patients who are at increased risk for atherosclerotic cardiovascular (CV) disease but with no known symptomatic CV disease. The trial tests the hypothesis that a Cleerly Coronary Artery Disease (CAD) Staging System-based care strategy reduces CV events compared with risk factor-based care.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: None

Interventions / Regimen

  • Device: The Cleerly CAD Staging System — The Cleerly CAD Staging System is software that utilizes a proprietary algorithm to identify CAD, stage the severity of CAD when present, and generate a prognostic risk score to inform treatment decisions that support CV disease prevention.

Primary Outcomes

  • The primary objective is to compare Cleerly stage-based care with risk factor-based care on the risk of CV events. (Through study completion- an average of 3.5 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-03-06
Completion: 2029-03-05
Eligibility
Age: 55 Years and older
Sex: ALL
Volunteers: true
Enrollment: 7500 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Cleerly, Inc.
Collaborators: CPC Clinical Research
Principal Investigators:
  • Deepak Bhatt, MD, MPH (STUDY_CHAIR) - Mt. Sinai Heart
  • David J. Maron, MD, FASPC (STUDY_CHAIR) - Stanford University
Contact Information
Study Contact:
Ryann Sardinia
7207398191
ryann.sardinia@cleerlyhealth.com
Ashley Dunham, PhD
7207398191
ashley.dunham@cleerlyhealth.com
Muhammad Salim, MD
Chandler Clinical Trials
Interventions
  • Device: The Cleerly CAD Staging System — The Cleerly CAD Staging System is software that utilizes a proprietary algorithm to identify CAD, stage the severity of CAD when present, and generate a prognostic risk score to inform treatment decisions that support CV disease prevention.
Study Locations (125 sites)
Chandler Clinical Trials, Chandler, Arizona 85224 United States
Scottsdale Clinical Trials, Scottsdale, Arizona 85260 United States
Sun City Research, Sun City, Arizona 85381 United States
Noble Clinical Research, Tucson, Arizona 85704 United States
Cardiovascular Research Foundation of Southern California, Beverly Hills, California 90210 United States
Amicis Research: Beverly Hills, Beverly Hills, California 90211 United States
Valiance Clinical Research - Canoga Park, Canoga Park, California 91303 United States
Cardiovascular Institute of San Diego, Chula Vista, California 91911 United States
Amicis Research: Granada Hills, Granada Hills, California 91324 United States
Valiance Clinical Research: Huntington Park, Huntington Park, California 90255 United States
Eligibility Criteria
Inclusion Criteria: 1. Provided electronic or written informed consent 2. Men \> 55, women \> 65 years of age 3. Type 2 diabetes mellitus requiring pharmacologic therapy, prediabetes (most recent HbA1c 5.7 to 6.4% and/or fasting glucose 100-125 mg/dL \[5.6-6.9 mmol/L\]) and/or metabolic syndrome. Metabolic syndrome is defined as \> 3 of the following criteria (International Diabetes Federation 2006): * Body mass index ≥ 27 kg/m2 or abnormal waist circumference defined as ≥ 80 cm (31.5 inches) for women, ≥ 94 cm (37 inches) for men; for South and East Asian men (e.g., Asian Indian, Chinese, Japanese) ≥ 90 cm (35.4 inches) * Fasting triglycerides ≥ 150 mg/dL (1.7 mmol/L) or treated hypertriglyceridemia * HDL-cholesterol (HDL-C) \< 40 mg/dL (1.03 mmol/L) in men, \<50 mg/dL (1.29 mmol/L) in women or treatment for this lipid abnormality * Systolic blood pressure (BP) ≥ 130 and/or diastolic BP≥ 85 mm Hg and/or treated hypertension * Fasting blood glucose ≥ 100 mg/dL (5.6 mmol/L) or HbA1c ≥ 5.7% 4. Have a device (e.g., smartphone, tablet, computer) for communication with the central cardiologist-led team managing drug treatment for the personalized care group Exclusion Criteria: 1. History of symptomatic CVD defined as prior MI, exertional or unstable angina, ischemic stroke, claudication, arterial revascularization for atherosclerosis or other CVD being actively managed by a cardiologist, e.g. atrial fibrillation, heart failure 2. Planned arterial revascularization 3. Inability to complete screening CCTA or any condition that would increase the risk associated with CCTA or increase likelihood of uninterpretable scan including: 1. eGFR \< 60 mL/min/1.73 m2 by the Chronic Kidney Disease Epidemiology Collaboration (CKD EPI) or Modification of Diet in Renal Disease (MDRD) equation (www.kidney.org/professionals/kdoqi/gfr\_calculator) 2. Allergy to iodinated contrast or history of contrast-induced nephropathy (including adverse reaction to contrast at screening CCTA) or screening laboratory values consistent with untreated hyperthyroidism. Participants with elevated thyroid-stimulating hormone (TSH) may be enrolled but should be referred to their physician for evaluation for treatment. 3. Thyroid cancer in the previous five (5) years or planned radioactive iodine treatment 4. Weight \> 300 lbs. (136 kg) or above manufacturer-recommended limit for scanner and table at the site 5. Inability to hold breath for \> 10 seconds 6. Active arrhythmia (atrial fibrillation, atrial flutter, frequent premature atrial, or ventricular contractions) with poorly controlled rate (i.e., \> 80 beats per minute at screening or prior to CCTA) 7. Contraindication to dosing with beta blocker or nitroglycerin on day of screening CCTA 8. Any other factor that, in the opinion of the investigator, would increase participant risk or increase the chance of an uninterpretable CCTA 4. Unsuitable as a trial participant in the opinion of the investigator for reasons including significant left main stenosis (e.g. ≥ 70%; site will be notified by Cleerly), other health condition with life expectancy \< 3 years or being at risk of poor compliance with study procedures (e.g., active substance abuse or untreated mental illness that, in the opinion of the investigator, is likely to adversely affect adherence or retention)

Maternal Mental Health Access - MaMa

NCT06049433
Recruiting
Conditions Postpartum Depression, Perinatal Depress...
Phase NA
Enrollment 120
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This hybrid effectiveness-implementation project will allow the team to evaluate and refine implementation in preparation for future multisite trials to ultimately move the Evidence-Based Intervention (EBI) to scale among diverse populations. The plan is to enroll 120 at-risk pregnant and postpartum women from rural, urban, and Latino populations. Using a randomized preference design to also evaluate patient and sociocultural factors in participation and symptom trajectory. Using the Implementation Research Logic Model, the team will evaluate the implementation feasibility and acceptability of a remote-access and on-demand MBCT PD prevention intervention that is integrated within maternal clinical care settings using an existing patient portal. Successful achievement of the study aims will result in a refined implementation protocol for future studies that are sufficiently powered to evaluate the effectiveness of an integrated Digital Mental Health Technology and to estimate the cost/benefit ratio

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Supportive Care Masking/blinding: None

Interventions / Regimen

  • Behavioral: Maternal Mental Health Access for Postpartum Depression- Prevention and UPLIFT- intervention — The intervention uses a standardized, manualized program (UPLIFT - Using Practice and Learning to Increase Favorable Thoughts) based on Mindfulness-Based Cognitive Behavioral Therapy (MBCT) in the prevention of depression in various populations and settings. MBCT can be delivered individually and in groups and via electronic platforms, in diverse populations. We have adapted UPLIFT for this study, based on input from focus groups and in response to the ongoing pandemic, and under the direction of our team's mental health professionals. Adaptations include access to asynchronous, on-demand multi-media MBCT content (digital audio-video files and downloadable content),
  • Behavioral: On-Demand + Discussion board (DB) — Adaptations include access to asynchronous, on-demand multi-media MBCT content (digital audio-video files and downloadable content), as well as synchronous Videoconference (VC) reduced from 8 weekly one-hour sessions to 4 one-hour sessions every two weeks. a discussion board with the potential to build a sense of community in a similar way that synchronous VC groups provide.
  • Behavioral: Arm 2 — The intervention uses a standardized, manualized program (UPLIFT - Using Practice and Learning to Increase Favorable Thoughts) based on Mindfulness-Based Cognitive Behavioral Therapy (MBCT) in the prevention of depression in various populations and settings. MBCT can be delivered individually and in groups and via electronic platforms, in diverse populations. On-demand multi-media MBCT content (digital audio-video files and downloadable content)
  • Behavioral: On Demand (OD) + Video Conference (VC) — on-demand multi-media MBCT content (digital audio-video files and downloadable content), as well as synchronous Videoconference (VC) reduced from 8 weekly one-hour sessions to 4 one-hour sessions every two weeks. A discussion board with the potential to build a sense of community in a similar way that synchronous VC groups provide.
  • Behavioral: Arm 3 — The intervention uses a standardized, manualized program (UPLIFT - Using Practice and Learning to Increase Favorable Thoughts) based on Mindfulness-Based Cognitive Behavioral Therapy (MBCT) in the prevention of depression in various populations and settings.
  • Behavioral: On Demand (OD) + Video Conference (VC) — Access to asynchronous, on-demand multi-media MBCT content (digital audio-video files and downloadable content), as well as synchronous Videoconference (VC)

Primary Outcomes

  • Implementation outcome; Feasibility and acceptability ((6, 12 & 18 months))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-04-04
Completion: 2025-12-30
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: true
Enrollment: 120 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Utah
Collaborators: National Institute of Nursing Research (NINR)
Principal Investigators:
  • Gwen Latendresse (PRINCIPAL_INVESTIGATOR) - University of Utah
Contact Information
Study Contact:
Gwen Latendresse, PhD CNM
(801) 587-9636
gwen.latendresse@nurs.utah.edu
Julie Neuberger, BS
801-587-3930
julie.neuberger@nurs.utah.edu
Gwen Latendresse, PhD CNM
801-587-9636
gwen.latendresse@nurs.utah.edu
University of Utah
Interventions
  • Behavioral: Maternal Mental Health Access for Postpartum Depression- Prevention and UPLIFT- intervention — The intervention uses a standardized, manualized program (UPLIFT - Using Practice and Learning to Increase Favorable Thoughts) based on Mindfulness-Based Cognitive Behavioral Therapy (MBCT) in the prevention of depression in various populations and settings. MBCT can be delivered individually and in groups and via electronic platforms, in diverse populations. We have adapted UPLIFT for this study, based on input from focus groups and in response to the ongoing pandemic, and under the direction of our team's mental health professionals. Adaptations include access to asynchronous, on-demand multi-media MBCT content (digital audio-video files and downloadable content),
  • Behavioral: On-Demand + Discussion board (DB) — Adaptations include access to asynchronous, on-demand multi-media MBCT content (digital audio-video files and downloadable content), as well as synchronous Videoconference (VC) reduced from 8 weekly one-hour sessions to 4 one-hour sessions every two weeks. a discussion board with the potential to build a sense of community in a similar way that synchronous VC groups provide.
  • Behavioral: Arm 2 — The intervention uses a standardized, manualized program (UPLIFT - Using Practice and Learning to Increase Favorable Thoughts) based on Mindfulness-Based Cognitive Behavioral Therapy (MBCT) in the prevention of depression in various populations and settings. MBCT can be delivered individually and in groups and via electronic platforms, in diverse populations. On-demand multi-media MBCT content (digital audio-video files and downloadable content)
  • Behavioral: On Demand (OD) + Video Conference (VC) — on-demand multi-media MBCT content (digital audio-video files and downloadable content), as well as synchronous Videoconference (VC) reduced from 8 weekly one-hour sessions to 4 one-hour sessions every two weeks. A discussion board with the potential to build a sense of community in a similar way that synchronous VC groups provide.
  • Behavioral: Arm 3 — The intervention uses a standardized, manualized program (UPLIFT - Using Practice and Learning to Increase Favorable Thoughts) based on Mindfulness-Based Cognitive Behavioral Therapy (MBCT) in the prevention of depression in various populations and settings.
Study Locations (1 sites)
University of Utah, Salt Lake City, Utah 84132 United States
Eligibility Criteria
Inclusion Criteria: * 18+ years of age, who at the time of screening * Have a viable pregnancy or are postpartum (up to 1 year) * Identified as at-risk for PD (any one of the following: * EPDS score equal to or greater than 9 or less than 21 * History of depression/anxiety * 2 or more significant life events) * English- or Spanish-speaking * Currently attending a UHealth clinic or rural public health partner clinic. Exclusion Criteria: * Have a substance use disorder * Current diagnosis of serious mental illness, such as psychosis, schizophrenia, bipolar disorder, severe depression (including EPDS \> 20) * Severe anxiety, suicidality, or currently taking any medications for a mental health condition.
Conditions Schizophrenia, Schizoaffective Disorder,...
Phase NA
Enrollment 85
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Deficiencies in social cognition are part of the core symptomatology of psychotic disorders. And deficiencies in social cognition, the closely related concept of metacognition, and, for example, paranoid attitudes are all associated with violence. The link between social cognition and violence is also observed through rehabilitation, as both group-based Social Cognition Interaction Training (SCIT) and group-based Metacognitive Skills Training (MCT) have reduced violent behavior in patients with psychotic disorders. Thus, a better knowledge of social cognition and its rehabilitation in psychotic disorders can help to reduce risky behavior and to rehabilitate the significant social difficulties often found in psychotic disorders. This research study aims to examine factors underlying the efficacy of group-based MCT. The goal of the metacognitive skills training group developed by Moritz and partners is to strengthen the social and metacognitive skills of the patients participating in the group. The group consists of 10 sessions during which exercises and discussion are emphasized. The themes of the group sessions are, for example, jumping to conclusions -bias, empathy, and memory. Detailed information is available from the MCT website (https://clinical-neuropsychology.de/metacognitive\_training-psychosis/). Overall there is meta-analysis-level evidence for the moderate effectiveness of MCT on positive symptoms of psychotic illnesses, such as delusions. Prior studies have argued that the unique factor underpinning MCT's efficacy is its impact on various cognitive biases, and that participating in the group especially reduces patients' tendency to jump to conclusions, which is a cognitive style associated with delusions and deficits in social perception and reasoning. As delusionality is related to the risk of violence, these results form a logical link between jumping to conclusions, delusionality, and violence. But the results regarding the effectiveness of MCT are still somewhat conflicting, and studies seem to be of varying quality. Additional longitudinal research and research related to the jumping to conclusion bias are also needed. The hypothesis regarding this study is that the MCT group reduces patients' tendency to jump to conclusions. These reductions are presumed to be associated in one-year follow-up with fewer mood symptoms, delusions, paranoia, and more psychological flexibility.

Design

Study type: Interventional Phases: Allocation: Non Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Behavioral: Metacognitive Skills Training (MCT) — The goal of the metacognitive skills training group developed by Moritz and co. is to strengthen the social and metacognitive skills of the patients participating in the group. The group consists of 10 sessions during which exercises and discussion are emphasized. The themes of the group sessions are, for example, jumping to conclusions -bias, empathy, and memory. Detailed information is available from the MCT website (https://clinical-neuropsychology.de/metacognitive\_training-psychosis/). Overall there is meta-analysis-level evidence for the moderate effectiveness of MCT on positive symptoms of psychotic illnesses, such as delusions. Prior studies have argued that the unique factor underpinning MCT's efficacy is its impact on various cognitive biases, and that participating in the group especially reduces patients' tendency to jump to conclusions, which is a cognitive style associated with delusions and deficits in social perception and reasoning.
  • Other: Treatment as usual — Medicinal treatment deemed appropriate by the attending physician, psychiatric ward treatment, and others forms of treatment recommended to the patients based on their treatment plans (e.g., work therapy, dialectical behavior therapy, talk therapy)

Primary Outcomes

  • Jumping to conclusions bias (For the intervention group, the measurement is done before the group and nine months after completion. For the control groups, the time interval is one year.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-09-01
Completion: 2026-12
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 85 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Jyvaskyla
Collaborators: Vanha Vaasa Hospital
Principal Investigators:
  • Raimo Lappalainen, PhD (PRINCIPAL_INVESTIGATOR) - University of Jyvaskyla
Contact Information
Study Contact:
Leo Kuutti, MA
029 524 3058
leo.kuutti@vvs.fi
Alice Keski-Valkama, PhD
029 524 3055
Alice.keski-valkama@vvs.fi
Leo Kuutti
+358295243058
leo.kuutti@vvs.fi
Vanha Vaasa Hospital
Interventions
  • Behavioral: Metacognitive Skills Training (MCT) — The goal of the metacognitive skills training group developed by Moritz and co. is to strengthen the social and metacognitive skills of the patients participating in the group. The group consists of 10 sessions during which exercises and discussion are emphasized. The themes of the group sessions are, for example, jumping to conclusions -bias, empathy, and memory. Detailed information is available from the MCT website (https://clinical-neuropsychology.de/metacognitive\_training-psychosis/). Overall there is meta-analysis-level evidence for the moderate effectiveness of MCT on positive symptoms of psychotic illnesses, such as delusions. Prior studies have argued that the unique factor underpinning MCT's efficacy is its impact on various cognitive biases, and that participating in the group especially reduces patients' tendency to jump to conclusions, which is a cognitive style associated with delusions and deficits in social perception and reasoning.
  • Other: Treatment as usual — Medicinal treatment deemed appropriate by the attending physician, psychiatric ward treatment, and others forms of treatment recommended to the patients based on their treatment plans (e.g., work therapy, dialectical behavior therapy, talk therapy)
Study Locations (1 sites)
Vanha Vaasa Hospital, Vaasa, Finland
Eligibility Criteria
Inclusion Criteria (patients): * Willingness to participate in a scientific study * Diagnosis of a psychosis spectrum disorder * Finnish language skills due to questionnaires and psychological tests being in Finnish Exclusion Criteria (patients): * Psychosis that severely deteriorates the ability to function * Cognitive problems that severely deteriorate the ability to function * Guardianship established for personal matters Inclusion Criteria (non-patient controls): * Willingness to participate in a scientific study * Self-assessed sufficient Finnish language skills due to questionnaires and psychological tests being in Finnish Exclusion Criteria (non-patient controls): * Diagnosis of a psychosis spectrum disorder * Cognitive problems that severely interferes with functioning
Conditions HER2-positive Breast Cancer, Early-stage...
Phase Not Applicable
Enrollment 300
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This is a prospective, multicenter, registry-based cohort study to explore the efficacy and safety of Pyrotinib combined with Capecitabine for adjuvant treatment of HER2 positive early breast cancer compared with treatment of physician's choice. Pyrotinib is a small molecule tyrosine kinase inhibitor which can irreversibly inhibit HER1, HER2, and HER4.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Drug: pyrotinib combined with Capecitabine — Pyrotinib 400mg, qd, po, day 1-21, q3w, Capecitabine 1000mg/m2, bid po d1-14, q3w
  • Drug: treatment of physician's choice — Treatment of physician's choice

Primary Outcomes

  • 3-year IDFS (3 Year)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2023-06-01
Completion: 2027-06-01
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 300 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Peking Union Medical College Hospital
Contact Information
Study Contact:
Xuefei Wang
861069158720
1210548954@qq.com
Xuefei Wang, Dr.
861069158720
1210548954@qq.com
Peking Union Medical College Hospital
Interventions
  • Drug: pyrotinib combined with Capecitabine — Pyrotinib 400mg, qd, po, day 1-21, q3w, Capecitabine 1000mg/m2, bid po d1-14, q3w
  • Drug: treatment of physician's choice — Treatment of physician's choice
Study Locations (1 sites)
Peking Union Medical College Hospital, Beijing, Beijing Municipality 100032 China
Eligibility Criteria
Inclusion Criteria: 1. Female patients ≥ 18 years and ≤ 75 years old; 2. Primary invasive breast cancer confirmed by histology; 3. HER2 positive breast cancer (IHC 3+, or IHC 2+ and FISH positive); lymph node positive, except for T0; lymph node negative and tumor \>1cm, or tumor \> 0.5 cm and ≤ 1cm, and accompanied by any of the following high-risk factors: pathological grade 3, ER/PR negative, or \< 35 years old; 4. Having received mastectomy or breast conserving surgery, and received sentinel lymph node biopsy or axillary lymph node dissection, and within 90 days from the breast surgery; 5. With known ER/PR status of breast cancer; 6. ECOG score 0-1; 7. The patient's major organ functions meet all of the following requirements for blood tests: 1. Neutrophil count (ANC) ≥ 1,500/mm3 (1.5×109/L); 2. Platelet count (PLT) ≥ 75,000/mm3 (75×109/L); 3. Hemoglobin (Hb) ≥ 8 g/dL (80 g/L); 4. Serum creatinine (SCr) ≤ 1.5 times the upper limit of normal (ULN) or creatinine clearance ≥ 60 mL/min; 5. Total bilirubin (TBIL) ≤ 1.5 times the upper limit of normal (ULN); 6. Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) level ≤ 2.5 times the upper limit of normal (ULN), patients with liver metastases should be ≤ 5×ULN. 9\. The participant voluntarily joins the study, signs the informed consent form, has good compliance, and cooperates with follow-ups. Exclusion criteria: 1. Breast cancer recurs before enrollment, or local recurrence/ metastasis confirmed by radiology; 2. The subject has participated in other clinical trials within 4 weeks or 5 half-lives (whichever is longer) before enrollment; 3. The patient has previously received treatment including tyrosine kinase inhibitors targeting HER2 (e.g., lapatinib, neratinib, and pyrotinib); 4. The patient has been diagnosed with other malignancies within 5 years of enrollment, except for cervical carcinoma in situ, basal cell carcinoma of the skin, or squamous cell carcinoma of the skin which has been cured; 5. The patient is receiving anti-tumor therapies from other clinical trials; 6. Inability to swallow, chronic diarrhea, or intestinal obstruction, with multiple factors affecting drug administration and absorption; 7. The patient has undergone major surgical procedures unrelated to breast cancer within 4 weeks of enrollment, or has not fully recovered from such surgical procedures; 8. With known allergies to any components of the agents to be administered in this study; history of acquired or congenital immunodeficiency diseases, including HIV; history of HCV, active hepatitis B, or history of organ transplantation; 9. Pregnant and lactating patients, patients of fertility unwilling to take effective contraceptive measures throughout the trial; 10. With any heart disease including: (1) arrhythmia requiring medication or clinical attention; (2) myocardial infarction; (3) heart failure; (4) any other heart diseases that are considered unsuitable to the trial; 11. With any comorbidities that are considered to potentially endanger the patient's safety or interfere with the study, including but not restricted to resistant hypertension, severe diabetes, active infection, etc.; 12. With a history of neurological or mental disorders, including but not restricted to epilepsy or dementia; 13. The patient is using CYP3A4 inhibitors or inducers, or any other drugs that potentially prolong the QT interval; 14. Any other circumstances in which the researcher believes that the patient is not suitable to participate in this study.
Conditions Ductal Carcinoma in Situ
Phase PHASE2
Enrollment 400
Locations 28 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this trial is to see if active surveillance monitoring and hormonal therapy in patients diagnosed with ductal cell carcinoma in situ (DCIS), an early stage of breast cancer, can be an effective management of the disease. Participants will be asked to receive control hormonal therapy or an investigational hormonal therapy treatment. Participants will be asked to return for evaluation with MRI at three months and six months. Depending on the evaluation participants will have the option to continue on the treatment. If the evaluation suggests surgery is recommended, the participant will discontinue the study treatment and will undergo surgery. In addition to the treatment and MRI evaluation, participants will be asked to provide blood sample to understand their immune status, provide saliva sample for genetic testing, provide the study with a portion of the tissue or slides generated from tissue removed during surgery performed as part of their standard of care.

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Tamoxifen — For premenopausal women: 20 mg tamoxifen orally daily (standard dose) or 10 mg every other day (low dose). For postmenopausal women who are not tolerating an AI, investigators can change them to the low dose (10 mg every other day) or standard dose (20 mg) of tamoxifen.
  • Drug: Exemestane — For postmenopausal women: standard oral doses of AI of choice: exemestane 25 mg daily, or reduced exemestane dosing: 25 mg 3 times per week orally
  • Drug: Letrozole — For postmenopausal women: standard oral doses of AI of choice: letrozole 2.5 mg daily.
  • Drug: Anastrazole — For postmenopausal women: standard oral doses of AI of choice: anastrozole 1 mg daily.
  • Drug: Testosterone + Anastrazole — Investigational drug. Both pre- and post- menopausal subjects. 100mg testosterone in combination with 4mg anastrazole administered subcutaneously every 3 months for up to 3 years.
  • Drug: Elacestrant — Investigational drug. Both pre- and post- menopausal subjects. Elacestrant 400mg PO with food once daily up to 36 months.
  • Drug: Z-endoxifen — Investigational drug. Both pre- and post- menopausal subjects. (z)-endoxifen 10mg delayed release capsule 1 hour before a meal or 2 hours after a meal once daily for up to 36 months.

Primary Outcomes

  • Patients remaining on active surveillance at 7 months (7 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2024-02-17
Completion: 2033-11
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 400 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: QuantumLeap Healthcare Collaborative
Principal Investigators:
  • Laura Esserman, MD, MBA (PRINCIPAL_INVESTIGATOR) - University of California, San Fancisco - Department of Surgery
  • (Co-PI) Kelly Hewitt, MD, FACS (PRINCIPAL_INVESTIGATOR) - Huntsman Cancer Institute at the University of Utah
Contact Information
Study Contact:
Kim Nelson, RN
+1 (888) 343-9922
k.nelson@qlhc.org
Tammy Neseth, MA, CCRP
+1 (507) 269-8060
t.neseth@qlhc.org
Niloufar Abdollahi
415.476.3322
Niloufar.abdollahi@ucsf.edu
Berkeley Outpatient Center
Interventions
  • Drug: Tamoxifen — For premenopausal women: 20 mg tamoxifen orally daily (standard dose) or 10 mg every other day (low dose). For postmenopausal women who are not tolerating an AI, investigators can change them to the low dose (10 mg every other day) or standard dose (20 mg) of tamoxifen.
  • Drug: Exemestane — For postmenopausal women: standard oral doses of AI of choice: exemestane 25 mg daily, or reduced exemestane dosing: 25 mg 3 times per week orally
  • Drug: Letrozole — For postmenopausal women: standard oral doses of AI of choice: letrozole 2.5 mg daily.
  • Drug: Anastrazole — For postmenopausal women: standard oral doses of AI of choice: anastrozole 1 mg daily.
  • Drug: Testosterone + Anastrazole — Investigational drug. Both pre- and post- menopausal subjects. 100mg testosterone in combination with 4mg anastrazole administered subcutaneously every 3 months for up to 3 years.
Study Locations (28 sites)
Berkeley Outpatient Center, Berkeley, California 94158 United States
City of Hope -Duarte Cancer Center, Duarte, California 91010 United States
City of Hope - Lennar Foundation Cancer Center, Irvine, California 92618 United States
UCLA, Los Angeles, California 90095 United States
UCSF, San Francisco, California 94158 United States
City of Hope, South Pasadena, California 91030 United States
John Muir Health, Walnut Creek, California 94598 United States
Moffitt Cancer Center, Tampa, Florida 33612 United States
Winship Cancer Institute, Emory University, Atlanta, Georgia 30322 United States
University of Chicago Medical Center, Chicago, Illinois 60637 United States
Eligibility Criteria
Inclusion Criteria: A. Female, at least 18 years old B. Previous diagnosis of HR+ DCIS (at least 50% ER or PR; biopsy will have been performed previously at diagnosis) with or without microinvasion * Patients with a diagnosis of hormone positive DCIS who have undergone surgery with positive margins that have not been re-excised are candidates to enroll in the trial. C. Patients who have previously received endocrine therapy should have a washout period of at minimum 4-6 weeks prior to the screening MRI on the RECAST-DCIS trial D. Bilateral mammogram performed within up to 6 months (180 days) of the start of trial treatment may be used for screening evaluation. If a bilateral mammogram has been performed within 1 year (12 months) of the start of trial treatment, then a diagnostic unilateral mammogram within 6 months (180 days) of the start of trial treatment will be acceptable for screening evaluation. E. MRI performed on an I SPY (RECAST) approved scanner within 2 months (60 days) of the start of trial treatment for lesion evaluation may be used for screening evaluation. F. CBC w/ diff, CMP, and Lipid Panel within normal limits within a year of the start of trial treatment. Abnormal labs to be repeated within 60 days prior to the start of trial treatment. Patients will be considered eligible for screening labs that are abnormal or out-of-range if the investigator has deemed the lab results not-clinically significant G. Negative urine or serum pregnancy test within 1 month of the start of trial treatment H. Controlled HIV positive patients are allowed as long as their current medication does not contraindicate the study's investigational agent I. Willingness and ability to provide tumor samples for research Exclusion Criteria: A. Pregnant or actively breastfeeding women B. History of allergic reactions attributed to compounds of similar chemical or biologic composition to study agent based on review of the medical record and patient history C. Invasive carcinoma or identification of a mass on MRI that is subsequently biopsied and found to be invasive cancer D. Co-enrollment in clinical trials of pharmacologic agents requiring an IND E. Ongoing treatment for DCIS other than what is specified in this protocol F. Uncontrolled intercurrent illness, including psychiatric conditions, that would limit compliance with study requirements G. Medical history or ongoing gastrointestinal disorders potentially affecting the absorption of investigational agent and/or tamoxifen. Active inflammatory bowel disease or chronic diarrhea, known active hepatitis A/B/C\*, hepatic cirrhosis, short bowel syndrome, or any upper gastrointestinal surgery including gastric resection or banding procedures \*Active hepatitis, defined as: A (positive HA antigen or positive IgM); B (either positive HBs antigen or positive hepatitis B viral DNA test above the lower limit of detection of the assay); C (positive hepatitis C antibody result, and quantitative hepatitis C (HCV) ribonucleic acid (RNA) results greater than the lower limits of detection of the assay) H. Participants who are unable to swallow normally or unable to take tablets and capsules. Predictable poor compliance with oral treatment I. Participants with substantial MRI artifacts (e.g., related to localizer sequences, cardiac devices such as pacemakers, or other hardware) that render the lesion non-evaluable. J. Severe allergy or reaction history to MRI contrast. K. Participants currently undergoing or who have received treatment for another malignancy within the previous 6 months.
Conditions LVAD, Frailty, GI Bleed, Right Heart Fai...
Phase Not Applicable
Enrollment 150
Locations 7 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Durable left ventricular assist devices (dLVAD) have been increasingly utilized since the mid to late 1990s, with an uptick of utility starting in 2010 following expanded indications for therapy to not only include a bridge to transplantation strategy, but also for those individuals who suffer from advanced heart failure (HF) and do not qualify for cardiac transplantation. Despite the decreasing size of the newest generation devices leading to a lessened occurrence of adverse events, bleeding and infection still remain a concern for clinicians, as well as a general lack of predictability towards adverse events in individuals with a dLVAD in place. There is a lack of description in the literature currently, regarding the interface between what the pump data provides and what is seen in clinical practice. There also is little known about the effects of what is provided in the pump data, in correlation to quality-of-life following dLVAD implantation. Therefore, the purpose of this study is to prospectively analyze normal and abnormal pump data through pump operations such as suction events, low flow alarms as well as other adventitious alarms, PI events and power cable disconnects greater than 20 seconds, from the HeartMate 3 ® dLVAD in order to clinically correlate this data to quality of life, frailty and other various medical conditions and adverse events as defined by the Interagency Registry for Mechanically Assisted Circulatory Support (Intermacs). This will be achieved through two aims: 1) Evaluate the effectiveness of dLVAD pump operations data on clinical practice application (quality of life, frailty and various medical conditions, and adverse events such as GIB, RHF, infection, hypertension, arrhythmias and stroke); and 2) Evaluate correlations and relationships of longitudinal normal and abnormal dLVAD pump operations data, to demographic and clinical variables. This study is the first study to evaluate HeartMate 3 ® dLVAD pump operations data over time for effectiveness in the clinical practice.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Device: HeartMate 3 (R) left ventricular assist device — No direct intervention; this is prospective study analysis of pump data from the HeartMate 3 (R) left ventricular assist device with clinical correlation to a multitude of variables and conditions we see clinically

Primary Outcomes

  • Survival (12-months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2023-10-27
Completion: 2026-12-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 150 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: International Consortium of Circulatory Assist Clinicians
Collaborators: Abbott, Medical University of Vienna, Mayo Clinic, University of Florida, University of Utah, University of Kansas Medical Center, Medical University of South Carolina, University of Chicago, University of California, San Francisco
Principal Investigators:
  • Sarah E Schroeder, PhD MSN RN (PRINCIPAL_INVESTIGATOR) - International Consortium of Circulatory Assist Clinicians
Contact Information
Study Contact:
Sarah E Schroeder, PhD MSN RN
402-937-3595
sarah.schroeder@vadcoordinator.org
Thomas Schloglhofer, MSc
+43 650 7119129
thomas.schloeglhofer@meduniwien.ac.at
Sylvie Baudart
UCSF
Interventions
  • Device: HeartMate 3 (R) left ventricular assist device — No direct intervention; this is prospective study analysis of pump data from the HeartMate 3 (R) left ventricular assist device with clinical correlation to a multitude of variables and conditions we see clinically
Study Locations (7 sites)
UCSF, San Francisco, California 94143 United States
University of Florida, Gainesville, Florida 32611 United States
University of Chicago, Chicago, Illinois 60637 United States
University of Kansas Medical Center, Kansas City, Kansas 66103 United States
Mayo Clinic-Rochester, Rochester, Minnesota 55902 United States
MUSC, Charleston, South Carolina 29425 United States
University of Utah, Salt Lake City, Utah 84112 United States
Eligibility Criteria
Inclusion Criteria: * 18 years of age or older * Scheduled Heartmate 3 ® dLVAD implantation Exclusion Criteria: * \<18 years of age * Scheduled for dLVAD that is NOT a Heartmate 3 (R) device
Conditions Perinatal Depression, PerinatalAnxiety
Phase PHASE2, PHASE3
Enrollment 100
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Perinatal depression and anxiety (PDA) are the leading causes of maternal mortality in developed countries. Women with a history of depression have a 20 fold higher risk of PDA at subsequent pregnancies. The adverse outcomes extend beyond maternal well-being to long-term deficits in children and families. The gut-brain axis is a newly recognized key player in mental health disorders. Specifically, the microbial composition of the gut along with their metabolites are directly involved in disease onset and course. Recent clinical studies have identified diet as the most powerful environmental factor in manipulating gut microbiome. Given vulnerability and resistance of pregnant women to pharmacotherapy, particularly in those with a predisposition to mood disorders, as well as pregnant women's high motivation and commitment to improving gestational diet, a dietary/supplemental intervention to 'optimize' gut microbiome, is a favored approach in disease management. The study investigators aim to exploit microbial responsiveness to diet together with this maternal motivation, to alter the risk and severity of a universal public health concern that has dire and long-term consequences for new moms and their children. The investigators of this trial, will first study the challenges in pursuing a study aimed at changing the microbiome of pregnant women with a history of mood disorders. Pregnant women in their second trimester will be recruited. Each will be assigned or randomized to one of four groups that will use a combination of diet, supplementation with probiotics, fish oil or no intervention. Each participant will meet with the study team virtually every 3 months until 1 year after delivery. At each study visit participants will be required to complete some questionnaires about their food intake, mood, and other health related measures and will provide a stool sample using the stool collection kits provided. The findings from this study will help strategize for a larger study that will allow for comparison of the effects of diet, and/or supplementation with Omega-3 Fatty Acids (O3FA) and probiotics on the microbiome and the onset and severity of PDA.

Design

Study type: Interventional Phases: Phase2, Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: Double

Interventions / Regimen

  • Dietary Supplement: Fish oil — 1500mg EPA +1000mg DHA daily
  • Dietary Supplement: Probiotics — Combination strain of lactobacillus and bifidobacteria
  • Behavioral: Prebiotics — Dietary consult with follow-up to ensure target fiber intake is met.
  • Behavioral: Diet Quality — one time dietary consult at enrollment to discuss strategies to improve overall diet.

Primary Outcomes

  • Feasibility of participant recruitment (20 months)
  • Adherence to Supplement Intake (estimated using unused portion of supplements) (2 years)
  • Adherence to Supplement Intake (Number of missed doses/week) (2 years)
  • Adherence to Dietary Protocol (Using food frequency questionnaire) (2 years)
  • Completion of Study visits(Number of studies with completed tasks) (2 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2, PHASE3
Status: Recruiting
Start Date: 2024-08-15
Completion: 2028-03
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 100 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: The Canadian College of Naturopathic Medicine
Collaborators: Sunnybrook Health Sciences Centre, Lotte & John Hecht Memorial Foundation
Principal Investigators:
  • Neda Ebrahimi, PhD (PRINCIPAL_INVESTIGATOR) - Canadian College of Naturopathic Medicine
Contact Information
Study Contact:
Neda Ebrahimi, PhD
416-498-1255
nebrahimi@ccnm.edu
Sophie Grigoriadis, MD
416-480-5677
sophie.grigoriadis@sunnybrook.ca
Neda F Ebrahimi, PhD
4164981255
nebrahimi@ccnm.edu
Sunnybrook Health Science Center
Interventions
  • Dietary Supplement: Fish oil — 1500mg EPA +1000mg DHA daily
  • Dietary Supplement: Probiotics — Combination strain of lactobacillus and bifidobacteria
  • Behavioral: Prebiotics — Dietary consult with follow-up to ensure target fiber intake is met.
  • Behavioral: Diet Quality — one time dietary consult at enrollment to discuss strategies to improve overall diet.
Study Locations (1 sites)
Sunnybrook Health Science Center, Toronto, Ontario M4N 3M5 Canada
Eligibility Criteria
Inclusion Criteria * Women 18-43 years old * 12-35 weeks of gestation * Non-smoker/alcohol/recreational drug user * Financially stable * Clinical diagnosis of lifetime depression/anxiety or PDA but currently well * English speaking Exclusion Criteria: * Body Mass Index (BMI)≥30 * Low income (unable to afford basic daily needs (i.e., shelter, food, etc.) * Diagnosis with other major mental health disorders (Bipolar, Psychosis, Addiction, Schizophrenia); * Diagnosis with other severe medical conditions (i.e. epilepsy, neurological disorders, etc.) * Allergies to fish oils/ingredients in supplements * Conditions that require repeated/chronic antibiotic usage * Having a child with significant mental/physical disability * Single mothers without any kind of family support, * Cigarette, alcohol and recreational drug users * Women unwilling to switch to study product(s) * Multiparous women with young children (i.e. one or more children less than 4 years of age at the time of delivery) * Non-English Readers/Speakers
Conditions Depressive Symptoms, Anxiety
Phase NA
Enrollment 600
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Background: Symptoms of depression and anxiety are prevalent among Spanish university students. Minimally guided online interventions have shown promise in reducing symptomatology and preventing increased mental distress. There is a need to evaluate the effectiveness of guided preventive mental health interventions for depression and anxiety in university students. Methods: two-arm multicenter randomized controlled trial (RCT), addressed to undergraduate students from 6 public universities with symptoms of depression and/or anxiety. Students will be evaluated through an online survey assessing mental health problems, use of mental health services, sociodemographic variables, self-perceived health, childhood and adolescent adversities, recent stressful events, social networks, personality and university experiences. A total of 600 students will be randomly assigned to: intervention group (guided E-health prevention intervention) or control group (treatment as usual with self-monitoring). The intervention, in app format, is based on principles of cognitive behavioral therapy, includes weekly feedback based on content and participation from a psychologist and self-monitoring. Assessments will take place post-intervention (up to 6 weeks), at 6 months and 12 months after randomization. The primary outcome will be the reduction of depressive or anxiety symptoms post-intervention, assessed with the Patient Health Questionnaire-9 (PHQ-9), the Generalized Anxiety Disorder-7 (GAD-7) and the Patient Health Questionnaire-Anxiety and Depression Scale (PHQ-ADS). Secondary outcomes of the RCT will be mental wellbeing, academic stress, comorbid symptoms, and adherence. Analyses will be conducted on an intention-to-treat and per protocol basis. Discussion: The results of the PROMES-U RCT will provide valuable information on a guided preventive online intervention that could be delivered in the campus context. In addition, results will provide information on the positive impact of the intervention on other relevant factors involved in mental health among university students.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Behavioral: MyMoodCoach — The MyMoodCoach prevention intervention is an evidence-based online intervention based on cognitive-behavioral therapy principles such as behavioral activation, problem solving and challenging negative thoughts.

Primary Outcomes

  • Change of depressive symptoms (Up to 6 weeks, at 6 months and 12 months after randomization)
  • Change of anxiety symptoms (Up to 6 weeks and at 6 months and 12 months post randomization)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-10-25
Completion: 2025-11
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 600 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of the Balearic Islands
Collaborators: Hospital del Mar Research Institute (IMIM), Universitat Jaume I, Universidad Miguel Hernandez de Elche, Universitat Pompeu Fabra, Universidad de Zaragoza, University of Malaga, Instituto de Salud Carlos III
Principal Investigators:
  • Jordi Alonso (PRINCIPAL_INVESTIGATOR) - Hospital de Mar Medical Research Institute (IMIM)
Contact Information
Study Contact:
Jordi Alonso
93 316 07 60
jalonso@researchmar.net
PROMES-U Study
promes@researchmar.net
Miquel Roca, phD
971173267
mroca@uib.es
Miquel Roca
Interventions
  • Behavioral: MyMoodCoach — The MyMoodCoach prevention intervention is an evidence-based online intervention based on cognitive-behavioral therapy principles such as behavioral activation, problem solving and challenging negative thoughts.
Study Locations (1 sites)
Miquel Roca, Palma de Mallorca, Balearic Islands 07122 Spain
Eligibility Criteria
Inclusion Criteria: * Eligible participants are all undergraduate students at the 6 participating universities and students followed in the PROMES-U observational study * Having 18 years of age or more * Having literacy in Spanish * Having access to a smartphone (Android or Apple) * With mild or moderate depression and/or anxiety symptoms screened (i.e., depression (5≤ (PHQ-9) ≤14); and/or anxiety (5≤ GAD-7 ≤14). Exclusion Criteria: * Moderately severe or severe depression and/or anxiety (i.e., PHQ-9≥15 and/or GAD-7≥15) * High suicide risk * A history of severe psychiatric disorder (e.g., bipolar, psychosis) * Being on mental health treatment (i.e., medication, psychotherapy or other intervention) Students with high suicide risk will receive a clinical alert recommending them to visit a specialist and a list of available mental health resources.
Conditions Haplo-identical Transplantation, Transpl...
Phase NA
Enrollment 50
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Allogeneic hematopoietic stem cell transplantation (allo-HSC) is currently one of the only curative treatments for haematological malignancies with a poor prognosis, the realization of which presupposes the identification and availability of a compatible donor. In recent years, haploidentical transplants have been developed, a reliable alternative for patients who do not have 100% compatible donors. The development of haplo-identical transplants leads to an exponential increase in the use of intra-family donation. Intrafamilial donation of hematopoietic stem cells (HSC) has the advantages of lower financial cost and faster availability of the graft, thus avoiding the risk of relapse before the procedure. Nevertheless, intrafamilial donation raises clinical and ethical questions. Indeed, the psychological impact of intra-family donation on the donor cannot be overlooked. Thus, in the context of the development of haplo-identical transplants, measuring the impact of donation on donors (ascendants and descendants) will make it possible to assess the relevance of taking psychosocial aspects into consideration in the choice of donors, to assess the psychological impact of haplo-identical donation and to offer psychological support adapted to donors.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Other Masking/blinding: None

Interventions / Regimen

  • Other: Evaluate the evolution of the psychic state of the donors (ascendants and descendants), by means of questionnaires, within the framework of haplo-identical allograft. — Donors are included in the study during the pre-donation assessment. Completion of questionnaires + socio-demographic data CSH collection visit (V1): Visit at which donors are collected for CSH donation. Completion by the donor of the questionnaires Follow-up of donors at D90 (+/-7) post V1, D180 (+/-15D) post V1 and D360 (+/-15D) post V1. The donors participating in the study will complete the scales/questionnaires D360: Completion by the donor of the questionnaires + semi-structured interview by telephone if accepted by the participant

Primary Outcomes

  • Anxiety (D0 ; D90, D180 and D360)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-01-22
Completion: 2028-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 50 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Assistance Publique - Hôpitaux de Paris
Principal Investigators:
  • Eolia Brissot (PRINCIPAL_INVESTIGATOR) - Assistance Publique - Hôpitaux de Paris
Contact Information
Study Contact:
Eolia Brissot
01 49 28 34 38
eolia.brissot@aphp.fr
Alice Polomeni
01 49 28 34 38
alice.polomeni@aphp.fr
Eolia Brissot
eolia.brissot@aphp.fr
Service D'hématologie Clinique et thérapie cellulaire - Hôpital St Antoine
Interventions
  • Other: Evaluate the evolution of the psychic state of the donors (ascendants and descendants), by means of questionnaires, within the framework of haplo-identical allograft. — Donors are included in the study during the pre-donation assessment. Completion of questionnaires + socio-demographic data CSH collection visit (V1): Visit at which donors are collected for CSH donation. Completion by the donor of the questionnaires Follow-up of donors at D90 (+/-7) post V1, D180 (+/-15D) post V1 and D360 (+/-15D) post V1. The donors participating in the study will complete the scales/questionnaires D360: Completion by the donor of the questionnaires + semi-structured interview by telephone if accepted by the participant
Study Locations (1 sites)
Service D'hématologie Clinique et thérapie cellulaire - Hôpital St Antoine, Paris, France
Eligibility Criteria
Inclusion criteria: * Identical haplo CSH donors ascending (parents) or descending (children) * Major identical haplo HSC donors * Haplo-identical HSC donors living in mainland France and cared for in the centers participating in the study * Haplo-identical HSC donors benefiting from Social Security System. * Haplo-identical HSC donors who have signed the consent form * \- Ability to read and write in French Exclusion Criteria: \- Insufficient understanding of the French language